Author(s):
Mendes, Cindy ; Martins, Filipa ; Granja, Sara ; Gonçalves, Joana ; Barros, Hélio ; Casimiro, Teresa ; Aguiar-Ricardo, Ana ; Silva, Fernanda ; Abreu, Bruna ; Cristovão, Miguel ; André, Saudade ; Pereira, Sofia A. ; Baltazar, Fátima ; Cabral-Marques, Helena ; Gaspar, Maria Manuela ; Gonçalves, Luís G. ; Bonifácio, Vasco D. B. ; Serpa, Jacinta
Date: 2025
Persistent ID: http://hdl.handle.net/10362/187507
Origin: Repositório Institucional da UNL
Project/scholarship:
info:eu-repo/grantAgreement/FCT/Concurso de avaliação no âmbito do Programa Plurianual de Financiamento de Unidades de I&D (2017%2F2018) - Financiamento Base/UIDB%2F04462%2F2020/PT;
info:eu-repo/grantAgreement/FCT/6817 - DCRRNI ID/UIDP%2F04462%2F2020/PT;
info:eu-repo/grantAgreement/FCT/Concurso de avaliação no âmbito do Programa Plurianual de Financiamento de Unidades de I&D (2017%2F2018) - Financiamento Base/UIDB%2F04612%2F2020/PT;
info:eu-repo/grantAgreement/FCT/Concurso de avaliação no âmbito do Programa Plurianual de Financiamento de Unidades de I&D (2017%2F2018) - Financiamento Programático/UIDP%2F04612%2F2020/PT;
info:eu-repo/grantAgreement/FCT/Concurso para Atribuição do Estatuto e Financiamento de Laboratórios Associados (LA)/LA%2FP%2F0087%2F2020/PT;
info:eu-repo/grantAgreement/FCT/OE/2020.06956.BD/PT;
info:eu-repo/grantAgreement/FCT//UI%2FBD%2F154203%2F2022/PT;
info:eu-repo/grantAgreement/FCT//SFRH%2FBD%2F148441%2F2019/PT;
info:eu-repo/grantAgreement/FCT/OE/2020.04780.BD/PT;
info:eu-repo/grantAgreement/FCT/OE/SFRH%2FBPD%2F111100%2F2015/PT;
Subject(s): Fourth-generation polyurea dendrimer functionalized with lactic acid (PUREG4-LA24); Metabolic remodeling; Metabolism-directed therapy; Non-small-cell lung carcinoma (NSCLC); Oxidative stress-induced ferroptosis; Reactive oxygen species (ROS); Selenium-containing chrysin (SeChry); Pharmacology; SDG 3 - Good Health and Well-being
Description
Funding Information: The institutions are funded by Fundação para a Ciência e a Tecnologia/Ministério da Ciência, Tecnologia e Ensino Superior (FCT/MCTES, Portugal) through national funds to iNO-VA4Health (UIDB/04462/2020 and UIDP/04462/2020), to MOSTMICRO-ITQB (UIDB/04612/2020 and UIDP/04612/2020) and the Associated Laboratory LS4FUTURE (LA/P/0087/2020). During the course of PhD, Cindy Mendes was funded by Liga Portuguesa Contra o Cancro –Nucleo regional Sul (LPCC-NRS) and by an FCT individual Ph.D. fellowship (2020.06956.BD). Isabel Lemos was funded by an FCT individual Ph.D. fellowship (UI/BD/154203/2022). Ana Hipólito was funded by a FCT individual Ph.D. fellowship (SFRH/BD/148441/2019). Filipa Martins was funded by a FCT individual Ph.D. fellowship (2020.04780.BD). Luis G. Gonçalves was financed by a FCT contract according to DL57/2016, [SFRH/BPD/111100/2015]. This work benefited from access to CERMAX, ITQB-NOVA, Oeiras, Portugal with equipment funded by FCT, project AAC 01/SAICT/2016. Publisher Copyright: © 2025 The Authors
Lung cancer is one of the most lethal cancers globally, primarily due to delayed diagnosis and lack of specific and effective therapy. Increased lactate production and consumption, along with cysteine metabolic reliance, are features identified in NSCLC in our recent studies. Cancer metabolic remodeling leads to excessive ROS production, triggering oxidative stress, promoting angiogenesis, causing cellular and tissue damage, and contributing to various pathophysiological changes. This study aimed to investigate the therapeutic potential of selenium–chrysin (SeChry), a cysteine metabolism inhibitor, and its delivery targeted at MCT1 by encapsulation in fourth-generation polyurea dendrimers functionalized with lactic acid (PUREG4-LA24), the nanoformulation SeChry@PUREG4-LA24, in NSCLC. We explored the impact of SeChry nanoformulation on cell death mechanisms, including ferroptosis, and its influence on angiogenesis in in vitro and in vivo models. SeChry@PUREG4-LA24 induces cell death through the induction of intracellular ROS and lipid peroxides, resulting in distinct expression patterns of ferroptosis-associated genes across cell lines. Experiments using chicken embryo chorioallantoic membrane (CAM) and mouse orthotopic xenograft models revealed a trend toward decreased tumor growth and angiogenesis with SeChry@PUREG4-LA24 administration. These findings suggest the potential of SeChry@PUREG4-LA24 as an innovative therapeutic approach for NSCLC, highlighting its impact on cell death mechanisms and anti-angiogenic effects.
